The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia

Clinical Pharmacokinetics

Volumn 34, Issue 3, 1998, Pages 227-263

  Ulrich, Sven ^a   Wurthmann, Cornelius ^a   Brosz, Matthias ^a   Meyer, Frank P ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT;

CLINICAL TRIAL; CONCENTRATION RESPONSE; DECISION MAKING; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; MEASUREMENT; META ANALYSIS; METHODOLOGY; PATIENT SELECTION; PREMEDICATION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; HALOPERIDOL; HUMANS; SCHIZOPHRENIA;

EID: 0031891375     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199834030-00005     Document Type: Review

References (128)

1. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151: 1409-16
2. Bassuk EL, Gerson S. Deinstitutionalisation and mental health services. Sci Am 1978; 238: 46-53
3. Berger PA. Medical treatment of mental illness: Pharmacotherapies revolutionize psychiatric care and present scientific and ethical challenges to society. Science 1978; 200: 974-81
4. Boston Consulting Group. The contribution of pharmaceutical companies: what's at stake for America. Boston (MA): Boston Consulting Group, 1993 Sep
5. Fatemi HS, Meltzer HY, Roth BL. Atypical antipsychotic drugs: Clinical and preclinical studies. In: Czernansky JG, editor. Handbook of experimental pharmacology. Vol. 120: antipsychotics. Berlin: Springer Verlag, 1996: 77-103
6. Gerlach J, Peacook L. New antipsychotics: the present status. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 39-48
7. Tamminga CA, Lahti AC. The new generation of antipsychotic drugs. Int Clin Psychopharmacol 1996; 11 Suppl. 2: 73-6
8. Mattes A. Risperidone: how good is the evidence for efficacy? Schizophr Bull 1997; 23: 155-61
9. Balant-Gorgia AE, Balant L. Antipsychotic drugs: clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokinet 1987; 13: 65-90
10. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma levels in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79-91
11. Eap CB, Koeb L, Baumann P. Artifacts in the analysis of thioridazine and other neuroleptics. J Pharmaceul Biomed Anal 1993; 11: 451-7
12. Schley J. Photo-decomposition and metabolism of the phenothiazine drug perazine. Drug Res 1986; 36: 635-637
13. Ulrich S. Sensitive gas-liquid chromatographic method for the assay of the neuroleptic drug cis(Z)-flupentixol in human serum or plasma. J Chromatogr B 1995; 668: 31-40
14. Rivera-Calimlim L, Hershey L. Neuroleptic concentrations and clinical response. Ann Rev Pharmacol Toxicol 1984; 24: 361-86
15. Dahl SG. Plasma level monitoring of antipsychotic drugs: clinical utility. Clin Pharmacokinet 1986; 11: 36-61
16. Preskorn SH, Burke MJ, Fast GA. Therapeutic drug monitoring: principles and practice. Psychiatr Clin North Am 1993; 16: 611-41
17. Lohse MJ, Müller-Oerlinghausen B. Psychopharmaka. In: Schwabe U, Paffrath D, editors. Arzneiverordnungsreport '96. Stuttgart: Fischer Verlag, 1996: 383-402
18. Wode-Helgodt B, Borg S, Fyrö B, et al. Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 1978; 58: 149-73
19. Rimon R, Averbuch I, Rozick P, et al. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptorassay during high-dose therapy of resistant schizophrenic patients. Psychopharmacol 1981; 73: 197-9
20. D'Agostino RB, Weintraub M. Meta-Analysis: a method for synthesizing research. Clin Pharmacol Ther 1995; 58: 605-15
21. Gibaldi M. Meta-analysis: a review of its place in therapeutic decision making. Drugs 1993; 46: 805-18
22. Froemming JS, Lam YWF, Jann MW, et al. Pharmacokinetics of haloperidol. Clin Pharmacokinet 1989; 17: 396-423
23. Midha KK, Hawes EM, Hubbard JW, et al. The search for correlations between neuroleptic plasma levels and clinical outcome: a critical review. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 1341-51
24. Rao ML. Zur Bedeutung der therapeutischen Serumspiegelüberwachung von Neuroleptika bei Nonresponse. In: Möller HJ, editor. Therapieresistenz unter Neuroleptikabehandlung. Wien: Springer Verlag, 1993: 85-97
25. Volavka J, Cooper ThB. Review of haloperidol blood level and clinical response: looking through the window. J Clin Psychopharmacol 1987; 7: 25-30
26. Forsman A, Ohman R. Applied pharmacokinetics of haloperidol in man. Curr Ther Res 1977; 21: 396-411
27. Haas S, Beckmann H. Pimozide versus haloperidol in acute schizophreina: a double blind controlled study. Pharmacopsychiatria 1982; 15: 70-4
28. McEvoy JP, Stiller RL, Farr R. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study. J Clin Psychopharmacol 1986; 6: 133-8
29. Ericksen StE, Hurt StW, Chang S, et al. Haloperidol dose, plasma levels, and clinical response: a double-blind study. Psychopharmacol Bull 1978; 14: 15-8
30. Möller HJ, Kissling W, Maurach R, et al. Beziehungen zwischen Haloperidol-Serumspiegel, Prolactin-Serumspiegel, antipsychotischem Effekt und extrapyramidalen Begleitwirkungen. Pharmacopsychiatria 1981; 14: 27-34
31. Möller HJ, Kissling W. Zur Frage der Beziehung zwischen Haloperidol-Serumspiegel und antipsychotischem Effekt. In: Heinrich K, Klieser E, editors. Probleme der neuroleptischen Dosierung. Stuttgart: Schattauer Verlag, 1987: 85-95
32. Bernardo M, Palao DJ, Arauxo A, et al. Monitoring plasma level of haloperidol in schizophrenia. Hosp Community Psychiatry 1993; 44: 115-8
33. Palao DJ, Arauxo A, Brunet M, et al. Haloperidol: therapeutic window in schizophrenia. J Clin Psychopharmacol 1994; 14: 303-10
34. Corvell W, Kelly M, Perry PJ, et al. Haloperidol plasma levels and acute clinical change in schizophrenia. J Clin Psychopharmacol 1990; 10: 397-402
35. Kelly MW, Perry PJ, Coryell WH, et al. Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia. Psychopharmacology 1990; 102: 514-20
36. Swigar ME, Jatlow PI, Goicoechea N, et al. Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis. Am J Psychiatry 1984; 141: 1281-3
37. Miller DD, Hershey LA, Duffy JP, et al. Serum haloperidol concentrations and clinical response in acute psychosis. J Clin Psychopharmacol 1984; 6: 305-10
38. Smith RC, Baumgartner R, Burd A, et al. Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatography and radioreceptor drug level assays. Psychopharmacol Bull 1985; 21: 52-8
39. Brown WA, Laughren Th, Chisholm E, et al. Low serum neuroleptic levels predict relapse in schizophrenic patients. Arch Gen Psychiatry 1982; 39: 998-1000
40. Cohen BM, Lipinski JF, Pope HG, et al. Neuroleptic blood levels and therapeutic effects. Psychopharmacol 1980; 70: 191-3
41. Cohen BM, Baldessarini RJ. Haloperidol and clinical response. Am J Psychiatry 1981; 138: 1513-4
42. Contreras S, Alexander H, Faber R, et al. Neuroleptic radioreceptor activity and clinical outcome in schizophrenia. J Clin Psychopharmacol 1987; 8: 95-7
43. Dunlop StR, Shea PhA, Hendrie HC. The relationship between plasma and red blood cell neuroleptic levels, oral dosage, and clinical parameters in a chronic schizophrenic population. Biol Psychiatry 1982; 17: 929-36
44. Michiels M, Hendricks R, Heykants J. Antibodies to haloperidol: a very sensitive tool for the radioimmunologic determination of some butyrophenones. Preclin Res Rep R1625/2. Beerse (Belgium): Janssen Pharmaceutica, 1976
45. Poland RE, Rubin RT. Radioimmunoassay of haloperidol in human serum: correlation of serum haloperidol with serum prolactin. Life Sci 1981; 29: 1837-45
46. Clark BR, Tower BB, Rubin RT. Radioimmunoassay of haloperidol in human serum. Life Sci 1977; 20: 319-26
47. Ulrich S, Meyer FP, Neuhof S, et al. Megabore capillary gas-liquid chromatographic method with nitrogen-phosphorus selective detection for the assay of haloperidol and reduced haloperidol in serum: results of therapeutic drug-monitoring during acute therapy of eight schizophrenics. J Chromatogr B 1995; 663: 289-96
48. Mendlewicz J, Linkowski P, Alexandre J, et al. Haloperidol plasma levels and clinical response in schizophrenia. In: Usdin E, Dahl SG, Gram LF, et al., editors. Clinical pharmacology in psychiatry. New York: Elsevier, 1981: 233-7
49. Neborsky R, Janowsky DS, Perel J, et al. Haloperidol plasma/red blood cell ratios and clinical efficacy. Psychopharmacol Bull 1982; 18: 17-20
50. Neborsky RJ, Janowsky DS, Perel JM, et al. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. J Clin Psychiatry 1984; 45: 10-3
51. Linkowski P, Hubain Ph, von Frenckell R, et al. Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatr Neurol Sci 1984; 234: 231-6
52. Bleeker JAC, Dingemans PM, Frohn-de Winter ML, et al. Plasma level and effect of low-dose haloperidol in acute psychosis. Psychopharmacol Bull 1984; 20: 317-9
53. Potkin StG, Shen Y, Zhou D, et al. Does a therapeutic window for plasma haloperidol exist?: preliminary chinese data. Psychopharmacol Bull 1985; 21: 59-61
54. van Putten Th, Marder StR, May RA, et al. Plasma levels of haloperidol and clinical response. Psychopharmacol Bull 1985; 21: 69-72
55. Shostak M, Perel JM, Stiller RL, et al. Plasma haloperidol and clinical response: a role for reduced haloperidol in antipsychotic activity? J Clin Psychopharmacol 1987; 7: 394-400
56. Aschauer HN, Schönbeck G, Langer G, et al. Plasma concentrations of haloperidol and prolactin and clinical outcome in acutely psychotic patients. Pharmacopsychiatria 1988; 21: 246-51
57. Neto MR, Müller-Spahn F, Rüther E, et al. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients. Pharmacopsychiatria 1988; 21: 226-31
58. Santos JL, Cabranes JA, Vazquez C, et al. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia. Biol Psychiatry 1989; 26: 381-8
59. Müller WE, Vogel P, Gattaz WF. Haloperidol: Plasmaspiegel und antipsychotische Wirksamkeit - Pharmakologische Erklärungsansätze für fehlende Korrelationen. In: Laux G, Riederer P, editors. Plasmaspiegelbestimmung von Psychopharmaka: Therapeutisches Drug Monitoring. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1992: 67-73
60. van Putten Th, Marder StR, Mintz J, et al. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992; 149: 500-5
61. Shostak M, Perel JM. Radioimmunoassay for haloperidol. Fed Proc 1976; 35: 531
62. Rubin RT, Forsman A, Heykants J, et al. Serum haloperidol determinations in psychiatric patients: comparison of methods and correlation with serum prolactin. Archs Gen Psychiatr 1980; 37: 1069-74
63. Pajersky J, Perel JM, Stiller RM. Comparison of gas chromatography and radioimmunoassay of haloperidol and applications in pharmacokinetic studies. Fed Proc 1982; 41: 1065
64. Wistedt B, Johanidesz G, Omerhodzic M, et al. Plasma haloperidol levels and clinical response in acute schizophrenia. Nord Psykiatr Tidsskr 1984; 9-13
65. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria for a selected group of functional disorders. 3rd ed. New York: Biometric Research Division, New York State Psychiatric Institute, 1977
66. American Psychiatric Association, Committee on Nomenclature and Statistics. Diagnostic and statistical manual of mental disorders. American Psychiatric Association, editor. 3rd ed. Washington, DC: American Psychiatric Press, 1980
67. Williams JBW, Spitzer RL. Research diagnostic criteria and DSM-III. Arch Gen Psychiatry 1982; 39: 1283-9
68. Soyka M. Die Alkoholhalluzinose: Klinik, Pathophysiologie und Therapie. Nervenarzt 1996; 67: 891-5
69. Jibiki I, Kubota T, Fujimoto K, et al. Effective clinical response at low plasma levels of haloperidol in Japanese schizophrenics with acute psychotic state. Jpn J Psychiatry Neurol 1993; 47: 627-9
70. Bjørndal N, Bjerre M, Gerlach J, et al. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology 1980; 67: 17-23
71. Gerlach J, Behnke K, Heltberg J, et al. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. Br J Psychiatry 1985; 147: 283-8
72. Hollister LE, Kim DY. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients. Am J Psychiatry 1982; 139: 1466-8
73. Itoh H, Yagi G, Fujii Y, et al. The relationship between haloperidol blood levels and clinical responses. Prog Neuro-Psychopharmacol Biol Psychiatr 1984; 8: 285-92
74. Ko GN, Korpi ER, Kirch DG. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients. J Clin Psychopharmacol 1989; 9: 186-90
75. Rao VAR, Bishop M, Coppen A. Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. Br J Psychiatry 1980; 137: 518-21
76. Rimón R, Averbuch I, Rozick P, et al. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients. Psychopharmacology 1981; 73: 197-9
77. van Putten Th, Marshall BD, Liberman RP, et al. Systematic dose reduction in treatment-resistent schizophrenic patients. Psychopharmacol Bull 1993; 29: 315-20
78. Bigelow LB, Kirch DG, Braun T, et al. Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study. Psychopharmacol Bull 1985; 21: 66-8
79. Kirch DG, Bigelow LB, Korpi ER, et al. Serum haloperidol concentration and clinical response in schizophrenia. Schizophr Bull 1988; 14: 283-9
80. Cannon M, Jones P. Schizophrenia. J Neurol Neurosurg Psychiatry 1996; 61: 604-13
81. Volavka J, Cooper Th, Czobor P, et al. Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 1992; 49: 354-61
82. Volavka J, Cooper ThB, Czobor P, et al. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 1995; 52: 837-45
83. Moulin MA, Davy JP, Debruyne D, et al. Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients. Psychopharmacology 1982; 76: 346-50
84. Altamura C, Mauri M, Cavallaro R, et al. Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: preliminary evidences. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 689-94
85. Magliozzi JR, Hollister LE, Arnold KV, et al. Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am J Psychiatry 1981; 138: 365-7
86. Extein I, Augusthy KA, Gold MS, et al. Plasma haloperidol levels and clinical response in acute schizophrenia. Psychopharmacol Bull 1982; 18: 156-8
87. Mavroidis ML, Kanter DR, Hirschowitz J, et al. Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology 1983; 81: 354-6
88. Garver DL, Hirschowitz J, Glicksteen GA, et al. Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol 1984; 4: 133-7
89. Balant-Gorgia AE, Eisele R, Balant L, et al. Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. Eur Arch Psychiatry Neurol Sci 1984; 234: 1-4
90. Davis JM, Ericksen StE, Hur St, et al. Haloperidol plasma levels and clinical response: basic concepts and clinical data. Psychopharmacol Bull 1985; 21: 48-51
91. Smith RC. Plasma haloperidol levels and clinical response. Arch Gen Psychiatry 1987; 44: 1110-2
92. Stevens A, Mahal A, Gaertner HJ. Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia. Pharmacopsychiatria 1992; 25: 218-23
93. Doddi S, Rifkin A, Karajgi B, et al. Blood levels of haloperidol and clinical outcome in schizophrenia. J Clin Psychopharmacol 1994; 14: 187-95
94. Ulrich S, Neuhof S, Braun V, et al. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiatria. In press
95. Venitz J. Pharmacokinetic-pharmacodynamic modelling of reversible drug effects. In: Derendorf H, Hochhaus G, editors. Handbook of pharmacokinetic/pharmacodynamic correlation. Boca Raton: CRC Press, 1995: 1-34
96. Nordström A-L, Farde L, Wiesel F-A, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33: 227-35
97. Nyberg S, Farde L, Halldin Ch, et al. D2-dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152: 173-8
98. Asberg M, Cronholm B, Sjöqvist F, et al. Relationship between plasma level and therapeutic effect of nortriptyline. BMJ 1971; 4: 331-4
99. Seeman P. Therpeutic receptor-blocking concentrations of neuroleptics. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 5-13
100. Crow TJ, MacMillan JF, Johnson AL, et al. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148: 120-7
101. Convit A, Volavka J, Czobor P, et al. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia. Am J Psychiatry 1994; 151: 49-56
102. Awad AG, Hogan TP, Voruganti LNP, et al. Patients' subjective experiences on antipsychotic medication: implications for outcome and quality of life. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 123-32
103. Altamura AC. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia with particular reference to drug resistance. Schizophr Res 1992; 8: 187-98
104. Duncan E, Wolkin A, Angrist B, et al. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics. Biol Psychiatry 1993; 34: 523-8
105. Mauri MC, Vita A, Giobbio GM, et al. Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables. Int Clin Psychopharmacol 1994; 9: 3-7
106. Ramchand R, Wei J, Ramchand CN, et al. Increased serum IgE in schizophrenic patients who responded poorly to neuroleptic treatment. Life Sci 1994; 54: 1579-84
107. Bogerts B. Derzeitiger Stand der biologischen Schizophrenieforschung: Relevanz für die Therapie. In: Bundesärztekammer, editor. Fortschritt und Fortbildung in der Medizin. Köln: Deutscher Ärzteverlag, 1988: 294-9
108. Stevens A, Stevens I, Mahal A, et al. Haloperidol and lorazepam combined: Clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis. Pharmacopsychiatria 1992; 25: 273-7
109. Arana GW, Goff DC, Friedman H, et al. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry 1986; 143: 650-1
110. Fast DK, Jones BD, Kusalic M, et al. Effect of carbamazepine on neuroleptic plasma levels and efficacy. Am J Psychiatry 1986; 143: 117-8
111. Jann MW, Ereshevsky L, Sakland SR, et al. Effects of carbamazepine on haloperidol levels. J Clin Psychopharmacol 1985; 5: 106-9
112. Dose M, Emrich HM. Carbamazepin als Adjuvans der neuroleptischen Behandlung schizophrener Psychosen. In: Müller-Oerlinghausen B, Haas S, Stoll KD, editors. Carbamazepin in der Psychiatrie. Stuttgart: Georg Thieme Verlag, 1989: 225-30
113. Zwaag CV, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum levels ranges. Am J Psychiatry 1996; 153: 1579-84
114. Javaid JI, Janicak PG, Sharma RP, et al. Prediction of haloperidol steady-state levels in plasma after a single test dose. J Clin Psychopharmacol 1996; 16: 45-50
115. Olesen OV, Juul-Nielsen S, Rosenberg R. Neuroleptic treatment in a gerontopsychiatric department: serum concentrations of perphenazine and haloperidol. Nord J Psychiatry 1994; 48: 337-42
116. Devanand DP, Cooper T, Sackeim HA, et al. Low dose oral haloperidol and blood levels in Alzheimer's disease: a preliminary study. Psychopharmacol Bull 1992; 28: 169-73
117. 2 receptors. Eur J Pharmacol 1990; 27: 111-8
118. Korpi ER, Wyatt R. Reduced haloperidol: effects on striatal dopamine metabolism and conversion to haloperidol in the rat. Psychopharmacology 1984; 83: 34-7
119. Kirch DG, Palmer MR, Egan M, et al. Electrophysiological interactions between haloperidol and reduced haloperidol, and dopamine, norepinephrine and phencyclidine in rat brain. Neuropharmacology 1985; 24: 375-9
120. Chang W-H, Shieh Y-S, Liu H-Ch, et al. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol. Eur Neuropsychopharmacol 1994; 4: 119-26
121. Eyles DW, Stedman TJ, Pond SM. Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms. Psychopharmacology 1994; 116: 161-6
122. Bertilsson L, Dahl ML, Equist B, et al. Disposition of neuroleptics perphenazine, zuclopenthicol and haloperidol cosegregates with polymorphic debrisoquine hydroxylation. In: Gram LF, Balant LP, Meltzer HY, et al., editors. Clinical Pharmacology in Psychiatry. Berlin: Springer Verlag, 1993: 230-7
123. Chang WH, Chen TY, Lee CF, et al. Low plasma reduced haloperidol/haloperidol ratios in chinese patients. Biol Psychiatry 1987; 22: 1406-8
124. Ereshevsky L, Saklad SR, Jann MJ, et al. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. J Clin Psychopharmacol 1984; 4: 138-42
125. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 1994; 268: 380-7
126. Subramanyam B, Rollema H, Woolf Th, et al. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 1990; 166: 238-44
127. Eyles DW, McLennan HR, Jones A, et al. Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. Clin Pharmacol Ther 1994; 56: 512-20
128. Eyles DW, Avent KM, Stedman TJ, et al. Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Life Sci 1997; 60: 529-34